Zobrazeno 1 - 10
of 69
pro vyhledávání: '"multiple sclerosis spasticity"'
Autor:
Niklas Garde, Markus Heibel
Publikováno v:
Drugs in Context, Vol 13, Pp 1-13 (2024)
Spasticity and its related symptoms of spasms, pain, sleep disturbance and bladder dysfunction are common in persons with multiple sclerosis (MS) and may be interconnected through a common pathophysiology and/or may trigger and worsen each other. Tet
Externí odkaz:
https://doaj.org/article/dcf17276b59145cf80a63fb8534023d9
Autor:
Marie D’hooghe, Barbara Willekens, Valerie Delvaux, Miguel D’haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch, Veronica Popescu
Publikováno v:
BMC Neurology, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently respon
Externí odkaz:
https://doaj.org/article/b35cdd26c69c493c805e20213374e42a
Publikováno v:
Case Reports in Neurology, Vol 10, Iss 2, Pp 169-176 (2018)
Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune demyelinating disease of the central nervous system. Patients exhibit heterogeneous patterns of disabling symptoms, including spasticity. In the majority of patients with MS
Externí odkaz:
https://doaj.org/article/c5bf9d8277b147eeb32ea32abb67adbe
Publikováno v:
Journal of Education, Health and Sport, Vol 8, Iss 2, Pp 85-94 (2018)
Rehabilitation treatment in multiple sclerosis should be carried out continuously, can take place in the hospital, ambulatory as well as environmental conditions. In the traditional approach, it focuses on reducing the symptoms of the disease, such a
Externí odkaz:
https://doaj.org/article/e6b61ae426274cefb58761bd0ca06fe8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vermöhlen, Vanessa, Schiller, Petra, Schickendantz, Sabine, Drache, Marion, Hussack, Sabine, Gerber-Grote, Andreas, Pöhlau, Dieter
Background: Evidence-based complementary treatment options for multiple sclerosis (MS) are limited. Objective: To investigate the effect of hippotherapy plus standard care versus standard care alone in MS patients. Methods: A total of 70 adults with
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A35527
https://tud.qucosa.de/api/qucosa%3A35527/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A35527/attachment/ATT-0/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ines Reynoso-Moreno, Erika Vallini, Andrea Chicca, Jürg Gertsch, Britta Engelhardt, Silvia Tietz
Publikováno v:
Reynoso-Moreno, Ines; Tietz, Silvia; Vallini, Erika; Engelhardt, Britta; Gertsch, Jürg; Chicca, Andrea (2021). Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis. ACS pharmacology & translational science, 4(2), pp. 765-779. ACS Publications 10.1021/acsptsci.0c00214
The modulation of the endocannabinoid system (ECS) has shown positive results in animal models of multiple sclerosis (MS) and immune and inflammatory disorders. However, chronic administration of CB1 receptor agonists and degrading enzyme inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a52e79978f411adb414f8dd4b2c7c8d
https://doi.org/10.1021/acsptsci.0c00214
https://doi.org/10.1021/acsptsci.0c00214
Autor:
Valérie Delvaux, Barbara Willekens, Miguel D'haeseleer, Daniel Guillaume, Guy Nagels, Patrick Vanderdonckt, Marie B. D'hooghe, Veronica Popescu, Guy Laureys, Vincent Van Pesch
Publikováno v:
BMC NEUROLOGY
BMC Neurology, Vol. 21, no.1, p. 1-9 (2021)
BMC Neurology
BMC Neurology, Vol 21, Iss 1, Pp 1-9 (2021)
BMC neurology
BMC Neurology, Vol. 21, no.1, p. 1-9 (2021)
BMC Neurology
BMC Neurology, Vol 21, Iss 1, Pp 1-9 (2021)
BMC neurology
Background This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcdef7c42e1cc877a569fb5a355b016e
https://biblio.ugent.be/publication/01GVZB2V55PGXR14NPF52MNEMT
https://biblio.ugent.be/publication/01GVZB2V55PGXR14NPF52MNEMT
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.